Tolvaptan: Phase III data

In the double-blind, placebo-controlled, international Phase III SALT-2 trial in 243 patients, tolvaptan significantly increased the average daily

Read the full 185 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE